Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 136-140

  Dullaart, Robin P F ^a   van Pelt, L Joost ^a   Kwakernaak, Arjan J ^a   Dikkeschei, Bert D ^a   van der Horst, Iwan C C ^b   Tio, René A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Isala Klinieken ^*  (Netherlands)

Author keywords

Acute coronary syndrome; Atypical chest pain; Lipoprotein associated phospholipase A2; Non STEMI; STEMI

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN T;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONCARDIAC CHEST PAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DETERMINATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TURBIDIMETRY;

ACUTE CORONARY SYNDROME; ATYPICAL CHEST PAIN; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2); NON-STEMI; STEMI;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CHEST PAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MYOCARDIAL INFARCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84879710672     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.05.026     Document Type: Article

References (32)

1. Caslake M.J., Packard C.J. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005, 2:529-535.
2. Häkkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999, 19:2909-2917.
3. Wilensky R.L., Macphee C.H. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol 2009, 20:415-420.
4. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
5. Thompson A., Gao P., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544. Lp-PLA(2) Studies Collaboration.
6. Corsetti J.P., Ryan D., Rainwater D.L., et al. Lp(a) and risk of recurrent cardiac events in obese postinfarction patients. Obesity (Silver Spring) 2008, 16:2717-2722.
7. Maiolino G., Pedon L., Cesari M., et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One 2012, 7(10):e48171.
8. Dohi T., Miyauchi K., Ohkawa R., et al. Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography. Ann Clin Biochem 2012, 49:527-533.
9. Rallidis L.S., Tellis C.C., Lekakis J., et al. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol 2012, 60:2053-2060.
10. Di Angelantonio E., Gao P., et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012, 307:2499-2506. Emerging Risk Factors Collaboration.
11. Oldgren J., James S.K., Siegbahn A., Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007, 28:699-704.
12. Möckel M., Müller R., Vollert J., et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 2007, 96:604-612.
13. Ryu S.K., Mallat Z., Benessiano J., et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation 2012, 125:757-766.
14. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 trial. Circulation 2006, 113:1745-1752.
15. Ostadal P., Vondrakova D., Kruger A., et al. Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis Nov 10 2012, 11:153. 10.1186/1476-511X-11-153.
16. Willemsen H.M., de Jong G., Tio R.A., et al. Quick identification of acute chest pain patients study (QICS). BMC Cardiovasc Disord 2009, 9:24.
17. Willemsen H.M., van der Horst I.C., Nieuwland W., et al. The diagnostic value of soluble CD163 in patients presenting with chest pain. Clin Biochem 2009, 42:1662-1666.
18. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
19. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29:2909-2945.
20. Thygesen K., Alpert J.S., Jaffe A.S., et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Eur Heart J 2012, 33:2551-2567.
21. Dutch College of General Practitioners Standaard diabetes mellitus type 2. Huisarts Wet 2006, 3:137-152.
22. Constantinides A., van Pelt L.J., van Leeuwen J.J., et al. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest 2011, 41:820-827.
23. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
24. Liu C.F., Qin L., Ren J.Y., et al. Elevated plasma lipoprotein-associated phospholipase A2 activity is associated with plaque rupture in patients with coronary artery disease. Chin Med J (Engl) 2011, 124:2469-2473.
25. Markakis K.P., Koropouli M.K., Grammenou-Savvoglou S., et al. Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages. J Lipid Res 2010, 51:2191-2201.
26. Tsimikas S., Mallat Z., Talmud P.J., et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010, 56:946-955.
27. Kujiraoka T., Iwasaki T., Ishihara M., et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003, 44:2006-2014.
28. Constantinides A., Kerstens M.N., Dikkeschei B.D., et al. Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium. Eur J Clin Invest 2012, 42:1235-1243.
29. Braun L.T., Davidson M.H. Lp-PLA2: a new target for statin therapy. Curr Atheroscler Rep 2010, 12:29-33.
30. 2 mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med 2012, 23:633-638.
31. Charniot J.C., Khani-Bittar R., Albertini J.P., et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol Oct 23 2012, [pii: S0167-5273(12)01160-6 [e-pub ahead of print]].
32. Gregson J., Stirnadel-Farrant H.A., Doobaree I.U., Koro C. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 2012, 225:11-21.